MONCTON, NB, Dec. 19, 2017
/CNW/ - Organigram Holdings Inc. (TSX VENTURE:OGI) (OTCQB:OGRMF)
(the "Company" or "Organigram"), a leading licensed producer of
medical marijuana based in Moncton, New
Brunswick, is pleased to announce the appointment of
Paolo De Luca, CPA, CA, CFA as the
Company's Chief Financial Officer (CFO). Mr. De Luca will assume
the position effective December 19,
2017.
With a reputation for creative, high-energy leadership focused
on the growth of dynamic companies, Mr. De Luca regularly draws
upon his broad global experience and deep technical expertise to
deliver unique and nontraditional financial solutions to complex
issues supported by his sophisticated knowledge of capital markets,
finance, technical accounting, tax and regulatory matters.
"Paolo is a tremendous addition to the Organigram team," says
Greg Engel, CEO, Organigram. "His
wide-ranging experience in both public and private capital markets,
proven track record of successful financial stewardship and
negotiations, and transformational vision will be an asset to the
Company as we transition from a strictly medical enterprise into a
hybrid business including the adult recreational use market in
2018."
With more than 20 years of diversified financial business
experience, Mr. De Luca has held senior financial, investor
relations, and accounting leadership roles at companies including
West Face Capital, one of Canada's
leading alternative asset management firms; Meridian LNG; Potash
Ridge; C.A. Bancorp; and TD Securities. With this diverse industry
and international background, he has extensive experience with both
traditional and non-traditional financing and debt offerings, which
will be a tremendous asset to Organigram.
As Organigram CFO, Mr. De Luca will lead both the finance team
as well as the investor relations efforts of the Company and will
be based out of the Company's satellite office in Toronto while managing the finance team in
Moncton, NB.
Mr. De Luca is a graduate of York
University's Schulich School of Business.
Peter Hanson has been serving as
interim CFO since March 2016. Mr.
Hanson will be appointed as Director of Finance with Organigram and
the Company is grateful for his stewardship.
Additionally, Giselle Doiron,
formerly Director of Investor and Media Relations at Organigram has
accepted a new role within the Company in Human Resources. Investor
relations inquiries will be handled by Dylan Rogers, Investor Relations Analyst at
investorrelations@organigram.ca.
For more information, visit www.organigram.ca
About Organigram Holdings Inc.
Organigram Holdings Inc. is a TSX Venture Exchange listed
company whose wholly owned subsidiary, Organigram Inc., is a
licensed producer of medical marijuana in Canada. Organigram is focused on producing the
highest quality, condition specific medical marijuana for patients
in Canada. Organigram's facility
is located in Moncton, New
Brunswick and the Company is regulated by the Access to
Cannabis for Medical Purposes Regulations ("ACMPR").
Organigram has been ranked in the top ten Clean Technology
& Life Sciences Sector on the TSX Venture Exchange 50.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectations. Important factors - including the availability of
funds, consummation of definitive documentation, the results of
financing efforts, crop yields - that could cause actual results to
differ materially from the Company's expectations are disclosed in
the Company's documents filed from time to time on SEDAR (see
www.sedar.com). Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date of this press release. The Company disclaims any intention or
obligation, except to the extent required by law, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
SOURCE OrganiGram